TH Open
(Jul 2023)
Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan
- Naoki Matsumoto,
- Hiroto Abe,
- Ryohei Kawasaki,
- Yoshihito Tashiro,
- Mariko Noguchi-Sasaki,
- Suguru Harada,
- Koichiro Yoneyama,
- Tomomi Niino,
- Tetsuhiro Soeda,
- Yasushi Yoshimura
Affiliations
- Naoki Matsumoto
- ORCiD
- Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Hiroto Abe
- Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Ryohei Kawasaki
- Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Yoshihito Tashiro
- Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Mariko Noguchi-Sasaki
- ORCiD
- Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Suguru Harada
- Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Koichiro Yoneyama
- Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan
- Tomomi Niino
- Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan
- Tetsuhiro Soeda
- Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Yasushi Yoshimura
- Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- DOI
-
https://doi.org/10.1055/a-2122-7887
- Journal volume & issue
-
Vol. 07,
no. 03
pp.
e241
– e243
WeChat QR code